The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A large validation study of AI-powered PD-L1 analyzer compared to pathologists’ assessment of PD-L1 expression in lung cancer.
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Johnson & Johnson/Janssen; Kyowa Kirin International; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
Research Funding - Amgen (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD (Inst)
 
Kiyotaka Yoh
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi sankyo; Kyowa Kirin; Lilly Japan; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Naoki Furuya
No Relationships to Disclose
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly Japan; Merck; Nippon Boehringer Ingelheim; Nippon Kayaku; Novar Pharma; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Lilly Japan; Pfizer
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer Pharma Japan. (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Delta-Fly Pharma (Inst); EPS Corporation (Inst); Fortrea Japan (Inst); Gilead Sciences (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel International Inc (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Shingo Miyamoto
No Relationships to Disclose
 
Satoshi Oizumi
Honoraria - AstraZeneca; Bristol-Myers Squibb K.K.; Chugai Pharma; Eisai; Merck; MSD K.K.; Nihonkayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD K.K (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hidekazu Suzuki
Honoraria - AstraZeneca Japan; Chugai Pharma; MSD
 
Yu Tanaka
No Relationships to Disclose
 
Tetsuya Sakai
Honoraria - Amco; AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Merck; MSD; Novartis; Olympus; Taiho Pharmaceutical
Research Funding - Amgen; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Merck
 
Hiroki Izumi
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly; Merck; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Eisai/MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Hibiki Udagawa
Honoraria - AstraZeneca Japan; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; MSD; Novartis; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); MSD K.K. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eri Sugiyama
No Relationships to Disclose
 
Shigeki Umemura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; MSD; Takeda
Research Funding - Daiichi sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Shingo Matsumoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Lilly; Merck; Novartis
Research Funding - Chugai Pharma (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst)
 
Soohyun Hwang
Employment - Lunit
Stock and Other Ownership Interests - Lunit
 
Chang Ho Ahn
Employment - Lunit
Stock and Other Ownership Interests - Lunit
Patents, Royalties, Other Intellectual Property - Deep learning model of IHC images providing single cell level continuous quantification of target expression
 
Yuichiro Hayashi
No Relationships to Disclose
 
Noriko Motoi
Honoraria - AstraZeneca; Chugai Pharma; Novartis; Sakura FineTech Japan
Research Funding - Ono Pharmaceutical (Inst)
 
Genichiro Ishii
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Merck; Novartis; Riken Genesis; Roche Diagnostics Solutions; Takeda
Research Funding - Daiichi Sankyo (Inst); H.U. Group Holdings (Inst); Indivumed (Inst); Nihon Medi-Physics (Inst); Ono Pharmaceutical (Inst); Sumitomo Dainippon Pharma (Inst); Takeda (Inst)
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Lilly Japan; Merck; Nippon Kayaku; Novartis; Ono Pharmaceutical; RIKEN GENESIS CO., LTD.; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Amgen; Bayer HealthCare Pharmaceuticals Inc.,; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Guardant Health Japan Corp.; Haihe Biopharma Co., Ltd.; iTeos Therapeutics Inc.; Janssen; Lilly Japan; Novartis; Pharma Mar, S.A.; Syneos Health
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Life Technologies (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Precision Medicine Asia Co., Ltd. (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)